Study of BST06 cell therapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies an experimental cell therapy that uses your own immune cells collected from your tumor to fight the cancer. It aims to see if this approach is safe and effective for advanced liver cancer that has progressed after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have advanced liver cancer (hepatocellular carcinoma) that has already been treated with standard therapies and has worsened.
- Your tumor must show a specific marker (GPC3) — this will be checked by a biopsy.
- You need to have at least one tumor that can be safely biopsied to create the study treatment.
- Your liver function must be adequate (Child-Pugh score A to B7).
- You must have an expected survival of at least 3 months and be able to care for yourself (ECOG score 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This trial tests an immune therapy made from your own blood cells (CAR-T) to treat advanced, unresectable liver cancer. It’s designed for people whose tumor has a specific marker called B7H3 and who meet blood, organ, and safety requirements.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial tests a special type of immune cell therapy (called HBV-TCR T cells) that is designed to attack liver cancer cells that carry the hepatitis B virus. It may be given alone or combined with a pill called lenvatinib to see if it can shrink tumors and help people with advanced liver cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.